{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T05:00:33Z","timestamp":1785128433191,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Mini-abstract<\/jats:title>\n                    <jats:p>Hypophosphatasia (HPP) is a rare systemic disorder with impaired bone mineralization. In 49 Central and Eastern European patients, chronic pain, fractures, deformities, and calcifying periarthritis were frequent. Most had low TN-ALP; only one received asfotase alfa. Findings highlight underdiagnosis, high symptom burden, and need for improved care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Hypophosphatasia (HPP) is a rare, potentially life-threatening, progressive, systemic, inherited metabolic disorder caused by loss-of-function variants in the\n                      <jats:italic>ALPL<\/jats:italic>\n                      gene encoding tissue-nonspecific alkaline phosphatase (TNSALP).\n                    <\/jats:p>\n                    <jats:p>HPP is a multi-organ disease, with its hallmark feature impaired bone mineralization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>The objective of this study was to evaluate the prevalence of HPP in the Central and Eastern European (CEE) region and to assess the frequency of its clinical manifestations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted on 49 patients with clinically and genetically confirmed HPP. Detailed clinical information was available for 34 patients from five CEE countries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analyzed cohort consisted of 14 males and 20 females, with a mean age of 51 years, regardless onset. A total of 33 patients (97%) exhibited TN-ALP levels below the reference range. Only one patient received treatment with asfotase alfa. Chronic musculoskeletal pain was reported by 25 patients (73%), while tooth loss, fractures, and bone deformities were observed in 26%, 44%, and 18% patients, respectively. One patient had a bone mineral density (BMD) in the osteoporotic range, and three patients had a trabecular bone score (TBS) \u22641.23. Other clinical manifestations included calcifying periarthritis (7 patients), seizures (3), nephrocalcinosis (3), hypercalcemia (3), kidney stones (2), ectopic calcifications (1), and pseudogout (1).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study, based on one of the largest reported cohorts of HPP patients, highlights that chronic pain is the most prevalent symptom. Bone-related complications, such as fractures and deformities, and joint-related conditions, particularly calcifying periarthritis, are also frequent. These findings emphasize the need for greater awareness of HPP, along with dedicated research efforts to enhance patient care and improve access to effective treatments.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1892714","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:25:14Z","timestamp":1785126314000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prevalence of clinical manifestations among patients with hypophosphatasia in Central and Eastern European countries"],"prefix":"10.3389","volume":"17","author":[{"given":"M.","family":"Ku\u017ema","sequence":"first","affiliation":[{"name":"5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Payer","sequence":"additional","affiliation":[{"name":"5th Department of Internal Medicine, Comenius University Faculty of Medicine, University Hospital","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Petrovi\u010d","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Genetics, and Clinical Genetics, Comenius University Faculty of Medicine, University Hospital Bratislava","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Bandura","sequence":"additional","affiliation":[{"name":"Institute of Medical Biology, Genetics, and Clinical Genetics, Comenius University Faculty of Medicine, University Hospital Bratislava","place":["Bratislava, Slovakia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Szegedi","sequence":"additional","affiliation":[{"name":"Institute of Genomic Medicine and Rare Disorders, Semmelweis University","place":["Budapest, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Dzivite-Kri\u0161ane","sequence":"additional","affiliation":[{"name":"Endocrinology Centre, Children\u2019s University Hospital","place":["Riga, Latvia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"\u017derjav Tan\u0161ek","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, Diabetes, and Metabolic Diseases at the Division of Pediatrics, University Medical Centre Ljubljana","place":["Ljublana, Slovenia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Haschka","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of OEGK and AUVA Trauma Center Vienna-Meidling, 1st Medical Department, Hanusch Hospital, Vienna Bone and Growth Center","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Resch","sequence":"additional","affiliation":[{"name":"Center of Internal Medicine II, Osteology, Medical Faculty, Sigmund Freud University","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kocijan","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Osteology at Hanusch Hospital of OEGK and AUVA Trauma Center Vienna-Meidling, 1st Medical Department, Hanusch Hospital, Vienna Bone and Growth Center","place":["Vienna, Austria"]},{"name":"Sigmund Freud University, Medical Faculty of Bone Diseases","place":["Vienna, Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.03.013","article-title":"Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment","volume":"12","author":"Whyte","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2023.116947","article-title":"The Global ALPL gene variant classification project: Dedicated to deciphering variants","volume":"178","author":"Farman","year":"2024","journal-title":"Bone"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06844-1","article-title":"Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults","volume":"35","author":"Khan","year":"2024","journal-title":"Osteoporosis Int"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e220240","DOI":"10.1530\/EC-22-0240","article-title":"Growth and disease burden in children with hypophosphatasia","volume":"12","author":"H\u00f6gler","year":"2023","journal-title":"Endocrine Connect"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2014.10","article-title":"Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia","volume":"22","author":"Hofmann","year":"2014","journal-title":"Eur J Hum Genet EJHG"},{"key":"B6","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.bone.2018.01.022","article-title":"Hypophosphatasia: Biochemical hallmarks validate the expanded pediatric clinical nosology","volume":"110","author":"Whyte","year":"2018","journal-title":"Bone"},{"key":"B7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bone.2017.02.011","article-title":"Hypophosphatasia: an overview for 2017","volume":"102","author":"Whyte","year":"2017","journal-title":"Bone"},{"key":"B8","doi-asserted-by":"publisher","first-page":"764\u20137","DOI":"10.1007\/s00508-025-02546-2","article-title":"Inadequate pediatric reference ranges impede the diagnosis of X-linked hypophosphatemia and hypophosphatasia in Austria","volume":"137","author":"Steininger","year":"2025","journal-title":"Wien Klin Wochenschr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4130","article-title":"Burden of illness in adults with hypophosphatasia: Data from the Global Hypophosphatasia Patient Registry","volume":"35","author":"Seefried","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/jbm4.10223","article-title":"Bisphosphonate use and fractures in adults with hypophosphatasia","volume":"3","author":"Rassie","year":"2019","journal-title":"JBMR Plus"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115795","article-title":"Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic","volume":"144","author":"Desborough","year":"2021","journal-title":"Bone"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-023-06859-8","article-title":"The challenge of hypophosphatasia diagnosis in adults: results from the HPP International Working Group Literature Surveillance","volume":"35","author":"Brandi","year":"2024","journal-title":"Osteoporosis Int"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2014.03.003","article-title":"A simple high-performance liquid chromatography (HPLC) method for the measurement of pyridoxal-5-phosphate and 4-pyridoxic acid in human plasma","volume":"433","author":"Cabo","year":"2014","journal-title":"Clinica Chimica Acta; Int J Clin Chem"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.3390\/jcm13082263","article-title":"Hypophosphatasia presenting as a chronic diffuse pain syndrome with extra-articular calcifications","volume":"13","author":"Lehane","year":"2024","journal-title":"J Clin Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1186\/s13023-024-03366-9","article-title":"Pain, quality of life, and integral management in a cohort of patients diagnosed with hypophosphatasia in Colombia","volume":"19","author":"Rojas Mart\u00ednez","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1186\/s13023-019-1167-5","article-title":"Burden of disease in pediatric patients with hypophosphatasia: results from the HPP Impact Patient Survey and the HPP Outcomes Study Telephone interview","volume":"14","author":"Rush","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e10395","DOI":"10.1002\/jbm4.10395","article-title":"Physical function and health related quality of life in adults treated with asfotase alfa for pediatric onset hypophosphatasia","volume":"4","author":"Genest","year":"2020","journal-title":"JBMR Plus"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000626","article-title":"Hypophosphatasia: from birth to adulthood","volume":"67","author":"Reis","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144855","article-title":"Alkaline phosphatase: Structure, expression and its function in bone mineralization","volume":"754","author":"Vimalraj","year":"2020","journal-title":"Gene"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05612-9","article-title":"Bone mineral density and fracture risk in adult patients with hypophosphatasia","volume":"32","author":"Genest","year":"2021"},{"key":"B21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0042-1755909","article-title":"Identifying adult hypophosphatasia in the rheumatology unit","volume":"17","author":"Feurstein","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-021-06145-5","article-title":"Massive calcification around large joints in a patient subsequently diagnosed with adult-onset hypophosphatasia","volume":"33","author":"Koga","year":"2022"},{"key":"B23","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1159\/000540692","article-title":"Challenges in hypophosphatasia: Suspicion, diagnosis, genetics, management, and follow-up","volume":"98","author":"Montero-Lopez","year":"2025","journal-title":"Horm Res Paediatr"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf044","article-title":"The ALPL gene variant project: results of the first 100 reclassified variants","volume":"9","author":"Farman","year":"2025"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2741\u201351","DOI":"10.1101\/2024.07.17.24310437","article-title":"Circulating micro-RNAs in patients with hypophosphatasia results of the first micro-RNA analysis in HPP","volume":"110","author":"Haschka","year":"2025","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1892714\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:25:14Z","timestamp":1785126314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1892714\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1892714"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1892714","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"article-number":"1892714"}}